The selected antibodies were target therapies against tumours expressing HER2, MET, FGFR2 or EGFR amplifications, MAPK/PIK3CA alterations, or immune deregulations (MSI, EBV, CPS ≥ 10 or TMB ≥ 15 mut/Mb). The gene discussed is ERBB2; the disease is neoplasm.